Navigation Links
Valeant Pharmaceuticals Intends to Raise Offer for Afexa Life Sciences Inc. to $0.85 per Share
Date:9/26/2011

MISSISSAUGA, Ontario, Sept. 26, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX), announced today that it intends to raise its takeover offer for Afexa Life Sciences Inc. (TSX:FXA) of Edmonton, Alberta to $0.85 per common share, an increase of 20% from $0.71 originally offered under an agreement announced on August 30, 2011.  The increased offer is subject to Afexa's agreement to certain amendments to the support agreement, including a reduction in the minimum tender condition, which Valeant hopes to resolve in the coming days.

"We have decided to offer a premium to Paladin Labs' most recent proposal as we are able to attribute more value than Paladin to the Afexa business given both our larger scale and resources in Canada, coupled with our extensive international consumer footprint," stated J. Michael Pearson, chairman and chief executive officer. "While we normally don't participate in an auction process, given that our existing offer has the full support of the Board and Management of Afexa, we felt it was appropriate to continue to respond quickly to Paladin's hostile overtures."  

Stikeman Elliott LLP is acting as legal counsel to Valeant and RBC Capital Markets is acting as financial advisor to Valeant.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. is a multi-national specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Forward Looking Information

To the extent any statements made in this document contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the Securities Act of 193
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Valeant Pharmaceuticals to Refinance Senior Secured Credit Facilities
2. Valeant Pharmaceuticals Announces Mailing of Offer and Take-Over Bid Circular to Shareholders of Afexa
3. Valeant Pharmaceuticals to Present at Industry Conferences
4. Valeant Pharmaceuticals Announces Increase to Monetary Limit Under Its Securities Repurchase Program
5. Valeant Pharmaceuticals Files a Notice of Intention to Make a Normal Course Issuer Bid
6. Valeant Pharmaceuticals Completes Acquisition of Sanitas Group
7. Valeant Pharmaceuticals Announces Resignation of Michael Van Every From Valeants Board of Directors
8. Valeant Pharmaceuticals Reports 2011 Second Quarter Financial Results
9. Valeant Pharmaceuticals Announces Approval of Sublinox® in Canada
10. Valeant Pharmaceuticals Announces Distribution Agreement for Zuacta™ in Canada
11. Valeant Pharmaceuticals Agrees to Acquire Ortho Dermatologics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 30, ... Guidance   ... including Core Earnings and ... Highlights of Q1 results  ... Underlying core earnings and underlying core EPS were flat, year-to-year , ...
(Date:7/29/2015)... Pa. , July 29, 2015  Unilife Corporation ... ASX: UNS), a developer, manufacturer and supplier of injectable ... multifaceted financing strategy that provides the Company with flexibility ... Unilife has signed an equity purchase agreement ... Fund, LLC ("LPC"), a Chicago -based ...
(Date:7/29/2015)... , July 29, 2015  Ascendis Pharma A/S ... that applies its innovative TransCon technology to address significant ... a conference call on July 30, 2015, at 9:00 ... a Phase 2 pediatric study of once-weekly TransCon Growth ... the top-line results before the market opens on July ...
Breaking Medicine Technology:Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 2Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 3Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 4Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 5Unilife Announces Multifaceted Financing Strategy 2Unilife Announces Multifaceted Financing Strategy 3Unilife Announces Multifaceted Financing Strategy 4Unilife Announces Multifaceted Financing Strategy 5Ascendis Pharma A/S to Report Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone and Host Conference Call on Thursday, July 30, 2015 at 9:00 a.m. Eastern Time 2
... Kanghui Holdings (NYSE: KH ) ("Kanghui" or ... of orthopedic implants in China, today announced that all ... meeting held in Hong Kong on September 5, 2011 ... , Re-election of Mr. Yikang Jiang as a ...
... Discovery Labs, Inc. (Nasdaq: DSCO ) today ... Complete Response to the 2009 Complete Response Letter issued by ... (lucinactant) for the prevention of respiratory distress syndrome (RDS) ... will designate the Complete Response as a Class 2 ...
Cached Medicine Technology:China Kanghui Holdings Announces Shareholder Resolutions Adopted at 2011 Annual General Meeting 2Discovery Labs Submits SURFAXIN® Complete Response to FDA 2Discovery Labs Submits SURFAXIN® Complete Response to FDA 3Discovery Labs Submits SURFAXIN® Complete Response to FDA 4
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... 24/7 Care ... Angeles, Riverside, and San Bernardino, recently announced that the Centers for Medicare and Medicaid ... system of home health care providers. 24/7 Care At Home’s agency is one of ...
(Date:7/30/2015)... ... July 30, 2015 , ... OncLive®’s ... UCLA’s Jonsson Comprehensive Cancer Center (JCCC) mutually agreed to collaborate on ... OncLive’s editorial and marketing groups will help spread the news about the center’s ...
(Date:7/30/2015)... ... July 30, 2015 , ... Glidewell Laboratories, industry-leading ... of Inclusive™ magazine, its multimedia publication focused on implant dentistry, is now available ... issue, Volume 6, Issue 2, as well as past issues of the dental ...
(Date:7/30/2015)... FL (PRWEB) , ... July 30, 2015 , ... On ... than $2 billion in taxpayer money to fund the state’s large prison system, which ... country with the highest rates of incarceration. In light of President Obama’s recent reduction ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... Gummy ... including lip lowering, gum contouring and surgery, as well as the patented gum depigmentation ... that has made him popular with many patients from around the world. , “Like ...
Breaking Medicine News(10 mins):Health News:24/7 Care At Home Earns a 5-Star Rating from the Centers for Medicare and Medicaid (CMS) 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 3Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 4Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 3Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2
... In its efforts to promote Kerala as an ideal destination for ... in the US, Britain, Dubai, Muscat, Kuwait, Sri Lanka and the ... it has to be systematic and we have asked the CII ... the policy and when we announce it shortly we would become ...
... outbreak in the Sydney CBD is linked to the Royal ... suspect//. However, they could not confirm the link. ... bacteria belonging to the Legionella family, Legionella pneumophilia, have been ... in the Circular Quay area on New Year's Eve. ...
... University and pediatric specialists at Baylor College of Medicine have ... as passkeys that allows drugs to enter cancer cells. ... of the journal Organic and Biomolecular Chemistry. ,All ... Cell walls, or membranes, form a protective cocoon around the ...
... Hopkins Researchers have shown that a drug commonly used ... engineered mice with Marfan syndrome and also prevents muscle ... ,The results are reported online this week at Nature ... Harry "Hal" Dietz, M.D., discovered that treating Marfan mice ...
... took more control over choosing their breast cancer surgeon were ... surgeons and at a hospital affiliated with an accredited cancer ... or their health plan, according to a study led by ... ,The study looked at 1,844 women recently diagnosed with ...
... to have a beneficial effect on the health of men. Some ... the following // ,Vegetables like tomatoes, carrot, garlic and whole ... like oysters, shrimps and deep sea fish has the similar effect ... and nutrients and also help in secretion of gastric acid. The ...
Cached Medicine News:Health News:Buckyballs Used as 'Passkey' into Cancer Cells 2Health News:Common BP Drug Treats Muscular Dystrophy 2Health News:Common BP Drug Treats Muscular Dystrophy 3Health News:Are Women Seeing the Most Experienced Breast Cancer Surgeons? 2
... Finntip Filters are ideal ... methods, or for any work ... They are designed for pipetting ... samples, and other. For applications ...
Inquire...
... Aerosol barrier tips eliminate false ... Scientifically designed and tested, Promega Barrier ... working with amplified nucleic acids (PCR(a)), ... samples, forensic and serological specimens. , ...
... tips eliminate false signals and contamination ... tested, Promega Barrier Tips offer performance ... nucleic acids (PCR(a)), radioactive isotopes, tissue ... serological specimens. , ,Promega Barrier Tips ...
Medicine Products: